Analytical Data
-
基因名
IFNa9
- Application
-
别名
IFNa9；Ifa9；Interferon alpha-9
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P09235
-
表达区间
24-190aa
-
氨基酸序列
CDLPQTH NLRNKKILTL LAQMRRLSPL SCLKDRKDFG FPQEKVDAQQ IQEAQAIPVL SELTQQILTL FTSKDSSAAW NATLLDSFCT GLHQLLNDLQ GCLMQLVGMK ELPLTQEDSQ LAMKKYFHRI TVYLREKKHS PCAWEVVRAE VWRALSSSVN LLARLSEEKE
-
分子量
21.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon alpha 9 (IFNa9) is a member of the type I interferon family, which plays a crucial role in the immune response against viral infections and tumor development. This recombinant protein has gained attention due to its potential therapeutic applications in various diseases, including viral hepatitis, certain malignancies, and autoimmune disorders. Research on IFNa9 highlights its unique antiviral and antiproliferative properties, as well as its ability to modulate the immune system through the activation of signal transducer and activator of transcription (STAT) pathways. Compared to other interferons, IFNa9 exhibits a specific receptor interaction that may enhance its efficacy and reduce side effects in clinical applications. Recent studies have focused on elucidating the molecular mechanisms underlying its action, optimizing production methods for recombinant proteins, and exploring its potential synergistic effects when combined with other therapeutic agents. These investigations are crucial for advancing our understanding of IFNa9's role in immunotherapy and could pave the way for novel treatment strategies that harness its protective effects against viral infections and tumors. As research progresses, IFNa9 holds promise as a valuable tool in the fight against various diseases, necessitating further exploration into its mechanisms, safety, and clinical effectiveness.
